Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Gritstone bio, a leading clinical-stage biotechnology company, is making significant strides in the development of powerful vaccines. In a recent announcement, the company revealed that the Compensation Committee of its Board of Directors has granted three employees nonqualified stock options. These options allow the employees to purchase a total of 47,000 shares of Gritstone’s common stock at an exercise price of $2.41.

This move is part of an inducement to attract and retain top talent, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over a four-year period, with 25% becoming available on the first anniversary of the employees’ date of hire. Subsequently, 1/48th of the options will vest monthly, contingent upon the employees’ continued employment with Gritstone.

Gritstone bio is committed to revolutionizing the field of biotechnology by leveraging its innovative vectors and payloads. By training multiple arms of the immune system to target critical disease targets, the company is paving the way for groundbreaking advancements in the treatment and prevention of viral diseases and solid tumors. Their ultimate goal is to improve patient outcomes and eradicate disease altogether.

With a robust portfolio of product candidates, Gritstone bio is at the forefront of cutting-edge research. Collaborating with industry partners, the company is dedicated to pushing the boundaries of medical science. By harnessing the potential of their novel technologies, Gritstone bio is poised to make a lasting impact on the healthcare landscape.

Investors have shown great interest in Gritstone bio’s innovative approach, recognizing the company’s potential for significant growth and success. George E. MacDougall, an investor at Gritstone bio, expressed his confidence in the company’s future, stating, “We believe that Gritstone bio’s commitment to developing the world’s most potent vaccines positions them as a leader in the biotechnology industry.”

Gritstone bio’s achievements have not gone unnoticed by the media either. Dan Budwick, a representative from 1AB, praised the company’s groundbreaking work, highlighting their dedication to improving patient outcomes. Budwick emphasized the importance of Gritstone bio’s mission, stating, “Their efforts in advancing the treatment and prevention of diseases are commendable, and we are excited to see the positive impact they will have on the lives of patients.”

As Gritstone bio continues to make strides in the biotechnology sector, their commitment to innovation and patient well-being remains unwavering. With their visionary approach and collaborative efforts, the company is poised to transform the future of healthcare, offering hope to patients worldwide. To learn more about Gritstone bio and their groundbreaking research, visit their website at www.gritstonebio.com.